TenNor Therapeutics held its first Scientific Advisory Board (SAB) Meeting on June 13, 2014 in Suzhou. SAB members include Dr. Xiaodong Wang, Dr. Steven McKnight, Dr. Richard Losick and Dr. Kenneth Chang. Several members from TenNor’s Board of Directors also attended the meeting. SAB members reviewed the progress of TenNor’s R&D program and provided input on company’s future development strategy.

About TenNor Therapeutics

TenNor Therapeutics is a clinical-stage company specialized in the discovery and development of differentiated new drug products in diseases associated with bacterial infection and metabolism. TenNor possesses a unique multi-targeting drug conjugate technology platform and a strong new drug development pipeline with global IP protection. Several products are currently in late stage of clinical development, targeting H. pylori infection, implanted medical device infections, hepatic encephalopathy and irritable bowel syndrome with diarrhea. The company is committed to address the unmet needs in the disease area and provide safe and effective therapies for patients in China and around the world.

For more information, please visit: www.tennorx.com